Which amino acids accumulate in maple syrup urine disease?
What type of protein is keratin classified as?
Sweaty feet odor in urine is seen in which condition?
What does salvage purine synthesis refer to?
Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?
What is the end product of purine metabolism in humans?
Rate limiting step in pyrimidine synthesis?
Hereditary orotic aciduria Type-I is due to deficiency of?
Which of the following molecular interactions are found in the structure of DNA?
Which enzyme polymerises Okazaki fragments?
NEET-PG 2013 - Biochemistry NEET-PG Practice Questions and MCQs
Question 81: Which amino acids accumulate in maple syrup urine disease?
- A. Valine
- B. Leucine
- C. Isoleucine
- D. All branched-chain amino acids (Correct Answer)
Explanation: ***All branched-chain amino acids*** - Maple syrup urine disease (MSUD) is characterized by a deficiency in the **branched-chain alpha-keto acid dehydrogenase complex**, which is responsible for the breakdown of branched-chain amino acids (BCAAs). - This deficiency leads to the accumulation of **leucine, isoleucine, and valine**, along with their corresponding alpha-keto acids, in the blood and urine. - The distinctive **maple syrup odor** in the urine is caused by the accumulation of branched-chain keto acids derived from all three BCAAs. *Leucine* - While leucine is one of the BCAAs that accumulates in MSUD, it is not the *only* amino acid involved. - The accumulation of **leucine** is particularly associated with the severe neurological symptoms seen in MSUD, as it is the most neurotoxic of the three BCAAs. *Valine* - Valine is another BCAA that accumulates due to the metabolic block in MSUD. - However, the disease involves the accumulation of all three BCAAs, not just valine in isolation. *Isoleucine* - Isoleucine is the third BCAA that accumulates in MSUD due to the defective enzyme. - Like leucine and valine, isoleucine and its corresponding keto acid accumulate in blood and urine when the branched-chain alpha-keto acid dehydrogenase complex is deficient.
Question 82: What type of protein is keratin classified as?
- A. Conjugated protein
- B. Globular protein
- C. Cylindrical protein
- D. Fibrous protein (Correct Answer)
Explanation: ***Fibrous protein*** - **Keratin** is a structural protein characterized by its **elongated, filament-like structure**, which is typical of fibrous proteins. - Fibrous proteins like keratin provide **mechanical strength** and play a significant role in the structure of tissues such as skin, hair, and nails. - Other examples of fibrous proteins include collagen, elastin, and myosin. *Globular protein* - **Globular proteins** have a **compact, spherical shape** and are often water-soluble, serving functions like enzymes, transporters, or receptors (e.g., hemoglobin or albumin). - Keratin's primary role is structural, not catalytic or transport, and its shape is not compact or spherical. *Cylindrical protein* - While some proteins might have a somewhat elongated or tube-like structure, **"cylindrical protein" is not a standard biochemical classification** of protein type. - This term does not accurately describe the characteristic fibrous nature and function of keratin. *Conjugated protein* - **Conjugated proteins** contain a non-protein component (prosthetic group) such as a carbohydrate, lipid, or metal ion attached to the protein (e.g., glycoproteins, lipoproteins, hemoglobin). - Keratin is a **simple fibrous protein** composed only of amino acids without prosthetic groups, so it is not classified as a conjugated protein.
Question 83: Sweaty feet odor in urine is seen in which condition?
- A. Phenylketonuria
- B. Isovaleric acidemia (Correct Answer)
- C. Alkaptonuria
- D. Maple syrup urine disease
Explanation: ***Isovaleric acidemia*** - This condition is characterized by a distinctive "sweaty feet" odor in body fluids, including urine, due to the accumulation of **isovaleric acid**. - It results from a deficiency in the enzyme **isovaleryl-CoA dehydrogenase**, which is crucial for leucine metabolism. *Phenylketonuria* - Patients with **phenylketonuria (PKU)** typically have a "mousy" or "musty" odor in their urine, not a sweaty feet smell. - This is due to the accumulation of **phenylalanine** and its metabolites. *Maple syrup urine disease* - This metabolic disorder is named for the characteristic sweet, maple syrup-like odor of the urine, which is distinctly different from a sweaty feet odor. - It is caused by a defect in the metabolism of **branched-chain amino acids (leucine, isoleucine, and valine)**. *Alkaptonuria* - This condition is known for urine that turns **dark brown or black** upon standing or when exposed to air, due to the oxidation of **homogentisic acid**. - It does not produce a sweaty feet odor.
Question 84: What does salvage purine synthesis refer to?
- A. Synthesis of purine nucleotides from purine bases (Correct Answer)
- B. Synthesis of purine nucleotides from ribose-5-phosphate
- C. Synthesis of purine nucleotides from simple precursors (de novo synthesis)
- D. Synthesis of purine nucleotides from degraded RNA
Explanation: ***Synthesis of purine nucleotides from purine bases*** - **Salvage pathways** recycle pre-existing purine or pyrimidine bases (from nucleic acid degradation) by re-attaching them to a **ribose phosphate** to form a new nucleotide. - This process is energy-efficient as it bypasses several steps of the de novo synthesis pathway, utilizing enzymes like **adenine phosphoribosyltransferase (APRT)** and **hypoxanthine-guanine phosphoribosyltransferase (HGPRT)**. *Synthesis of purine nucleotides from ribose-5-phosphate.* - While **ribose-5-phosphate** is a precursor, the complete synthesis from this molecule is part of the **de novo pathway**, which starts with PRPP (phosphoribosyl pyrophosphate) formation from ribose-5-phosphate. - This option does not specify the direct reuse of a pre-formed purine base, which is the hallmark of salvage. *Synthesis of purine nucleotides from simple precursors (de novo synthesis).* - **De novo synthesis** is the creation of nucleotides from scratch using simple metabolic precursors like amino acids (glycine, aspartate, glutamine), CO2, and THF derivatives. - This contrasts with salvage pathways, which recycle existing bases. *Synthesis of purine nucleotides from degraded RNA.* - Degraded RNA breaks down into **nucleotides**, which can then be further broken down into **purine bases** and ribose phosphates. - The direct synthesis of purine nucleotides from *degraded RNA* involves recovering the individual bases or nucleosides, then converting them to nucleotides via salvage, not directly using the entire degraded RNA.
Question 85: Which of the following organs does not primarily utilize the salvage pathway of purine nucleotide synthesis?
- A. RBC
- B. Leukocytes
- C. Liver (Correct Answer)
- D. Brain
Explanation: ***Liver*** - The **liver** is capable of both *de novo* synthesis and the salvage pathway of purine nucleotides, but it primarily utilizes the **de novo pathway** due to its high metabolic capacity and central role in biosynthesis for the entire body. - While salvage pathways exist, the liver's robust *de novo* synthesis allows it to readily produce purines from simple precursors, making it less reliant on salvaging pre-formed bases. *Brain* - The **brain** relies heavily on the **salvage pathway** for purine nucleotide synthesis because it has a limited capacity for *de novo* purine synthesis. - This dependency makes the brain particularly vulnerable to deficiencies in salvage enzymes, such as in **Lesch-Nyhan syndrome** where HGPRT deficiency leads to severe neurological dysfunction. *RBC* - **Red blood cells (RBCs)** are anucleated and lack the machinery for *de novo* purine synthesis, making them entirely dependent on the **salvage pathway** to maintain their purine nucleotide pool. - They salvage pre-formed purine bases and nucleosides from the plasma to synthesize necessary adenine and guanine nucleotides. *Leukocytes* - **Leukocytes**, particularly lymphocytes, have a high turn-over rate and metabolic activity, and they primarily rely on the **salvage pathway** for purine nucleotide synthesis. - The **immune system's rapid proliferation** and response demand efficient nucleotide synthesis, and the salvage pathway offers a quick and energy-efficient way to achieve this.
Question 86: What is the end product of purine metabolism in humans?
- A. Uric acid (Correct Answer)
- B. Carbon Dioxide
- C. Allantoin
- D. None of the options
Explanation: ***Uric acid*** - **Uric acid** is the final breakdown product of **purine metabolism** in humans. - It is formed from the degradation of **adenosine** and **guanosine**, with xanthine oxidase playing a key role in its synthesis. *Allantoin* - **Allantoin** is the end product of **purine metabolism** in most mammals other than primates, as they possess the enzyme **uricase** to further break down uric acid. - Humans lack **uricase**, hence allantoin is not the end product in humans. *Carbon Dioxide* - **Carbon dioxide** is a major end product of **carbohydrate** and **fat metabolism** through cellular respiration. - It is not directly associated with the degradation pathway of purines. *None of the options* - This option is incorrect because **uric acid** is indeed the definitive end product of purine metabolism in humans.
Question 87: Rate limiting step in pyrimidine synthesis?
- A. Aspartate transcarbamoylase (ATCase)
- B. Dihydroorotate dehydrogenase
- C. Dihydro-orotase
- D. Carbamoyl phosphate synthase-II (Correct Answer)
Explanation: ***Carbamoyl phosphate synthetase II (CPS-II)*** - **CPS-II** is the **committed and rate-limiting enzyme** in **de novo pyrimidine synthesis** in **mammals (including humans)** - It catalyzes the formation of **carbamoyl phosphate** from glutamine, CO₂, and 2 ATP in the **cytoplasm** - This is the **first committed step** and the main **regulatory checkpoint**, inhibited by UTP (feedback inhibition) and activated by PRPP and ATP - CPS-II is part of the **CAD complex** (carbamoyl phosphate synthetase, aspartate transcarbamoylase, dihydroorotase) in mammals *Aspartate transcarbamoylase (ATCase)* - ATCase catalyzes the **second step**: condensation of carbamoyl phosphate with aspartate to form carbamoyl aspartate - While ATCase is the **rate-limiting step in bacteria** (E. coli), in **mammals** it is part of the CAD complex and **not the primary regulatory step** - This option is incorrect for human/mammalian biochemistry tested in NEET PG *Dihydro-orotase* - The **third enzyme** in the pathway, converting carbamoyl aspartate to dihydroorotate - Part of the CAD complex in mammals but **not the rate-limiting step** *Dihydroorotate dehydrogenase* - Catalyzes the **fourth step**: oxidation of dihydroorotate to orotate - Located on the **outer surface of the inner mitochondrial membrane** (only mitochondrial enzyme in the pathway) - Important enzyme but **not rate-limiting**
Question 88: Hereditary orotic aciduria Type-I is due to deficiency of?
- A. Orotate phosphoribosyl transferase
- B. UMP synthase (Correct Answer)
- C. Orotic acid decarboxylase
- D. All of the options
Explanation: ***UMP synthase*** - Hereditary orotic aciduria Type-I is caused by a deficiency of the **bifunctional enzyme UMP synthase** (also called UMP synthase complex). - UMP synthase catalyzes two sequential reactions in the *de novo* pyrimidine synthesis pathway: 1. **OPRT activity**: Converts orotate → orotidine 5'-monophosphate (OMP) 2. **ODC activity**: Converts OMP → uridine 5'-monophosphate (UMP) - This is the **most precise and complete answer** as it identifies the actual enzyme complex that is deficient. - **Clinical features**: Megaloblastic anemia, growth retardation, immunodeficiency; responds to oral uridine supplementation. *Orotate phosphoribosyl transferase* - This represents only **one of the two catalytic activities** of the UMP synthase enzyme (the first step). - While this activity is indeed deficient in Type-I orotic aciduria, naming only this activity is **incomplete** because the enzyme has two functions. - This would be a **partial answer** rather than the complete enzyme name. *Orotic acid decarboxylase* - This represents only **the second catalytic activity** of the UMP synthase enzyme (converts OMP to UMP). - Like OPRT, this activity is also deficient, but naming only this component is **incomplete**. - **Type II orotic aciduria** (extremely rare) involves isolated ODC deficiency without OPRT deficiency. *All of the options* - While technically both OPRT and ODC activities are affected in Type-I orotic aciduria, the **standard nomenclature** refers to the deficient enzyme as **"UMP synthase"** - the name of the complete bifunctional enzyme. - In medical terminology and examination context, we identify enzyme deficiencies by the **name of the enzyme complex**, not by listing all its individual catalytic activities. - Therefore, **"UMP synthase"** is the single most accurate and complete answer.
Question 89: Which of the following molecular interactions are found in the structure of DNA?
- A. Hydrogen bond
- B. Glycosidic bond
- C. Covalent interactions
- D. All of the options (Correct Answer)
Explanation: ***All of the options*** - All three types of molecular interactions listed are present in DNA structure, making this the correct answer. - **Hydrogen bonds** hold together the two strands of the DNA double helix, forming between complementary base pairs (A-T with 2 hydrogen bonds, G-C with 3 hydrogen bonds). - **Glycosidic bonds** (N-glycosidic bonds) link the nitrogenous bases to the C1' carbon of the deoxyribose sugar in each nucleotide. - **Covalent interactions** (phosphodiester bonds) form the strong, stable sugar-phosphate backbone by linking the 3' hydroxyl group of one sugar to the 5' phosphate group of the next. *Hydrogen bond* - This is a **true statement** - hydrogen bonds are essential structural components of DNA. - However, this option alone is **incomplete** as DNA structure also contains glycosidic bonds and covalent phosphodiester bonds. - If only hydrogen bonds were present, there would be no nucleotides or backbone structure. *Glycosidic bond* - This is a **true statement** - glycosidic bonds are present in every nucleotide of DNA. - However, this option alone is **incomplete** as DNA also requires hydrogen bonds for base pairing and phosphodiester bonds for the backbone. - Without other bonds, individual nucleotides could not form a functional double helix. *Covalent interactions* - This is a **true statement** - covalent phosphodiester bonds form the DNA backbone within each strand. - However, this option alone is **incomplete** as it doesn't account for glycosidic bonds (nucleotide formation) or hydrogen bonds (strand pairing). - While the strongest bonds in DNA, they alone cannot create the complete double helix structure.
Question 90: Which enzyme polymerises Okazaki fragments?
- A. DNA polymerase I
- B. DNA polymerase II
- C. DNA polymerase III (Correct Answer)
- D. RNA polymerase
Explanation: ***DNA polymerase III*** - **DNA polymerase III** is the primary replicative enzyme in **prokaryotes (bacteria)** responsible for synthesizing new DNA strands, including the **polymerization of Okazaki fragments** on the lagging strand. - It possesses high processivity (can add ~500 nucleotides without dissociating), essential for rapid and efficient DNA synthesis during replication, adding nucleotides in a **5' to 3' direction**. - In **eukaryotes**, DNA polymerase δ (delta) performs the analogous function of polymerizing Okazaki fragments. *DNA polymerase I* - **DNA polymerase I** in prokaryotes primarily functions in **removing RNA primers** left by primase and **filling the resulting gaps** with DNA nucleotides. - It has 5' to 3' exonuclease activity for primer removal and polymerase activity for gap filling, but is **not the main enzyme for elongating Okazaki fragments**. - Its role is in **DNA repair and finishing replication**, not the extensive synthesis of Okazaki fragments. *DNA polymerase II* - **DNA polymerase II** in prokaryotes is primarily involved in **DNA repair mechanisms**, particularly in **restarting stalled replication forks** and responding to DNA damage. - It is not the main enzyme responsible for the polymerization of **Okazaki fragments** during normal DNA replication. *RNA polymerase* - **RNA polymerase** (specifically **primase**, a specialized RNA polymerase) synthesizes short **RNA primers** (8-12 nucleotides) during DNA replication, which provide the 3'-OH group necessary to initiate DNA synthesis. - It does not synthesize DNA or polymerize **Okazaki fragments**; its function is to create RNA primers, not extend DNA strands.